The Food and Drug Administration has issued a Class I recall correction for certain Boston Scientific ACCOLADE pacemakers and cardiac resynchronization therapy pacemakers after identifying a software- ...
A novel leadless pacemaker designed for left bundle branch area pacing conferred successful pacing parameters at 1 month, but ...
Funding supports continued execution of Orchestra BioMed's pivotal trials for Atrioventricular Interval Modulation Therapy ("AVIM Therapy") and Virtue Sirolimus AngioInfusion Balloon ("Virtue SAB") ...
Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial ...
Ligand to $40 million to date in exchange for tiered royalty interest in Orchestra BioMed’s future revenue as well as equity Funding supports continued execution of Orchestra BioMed’s pivotal trials ...
Less than 1 percent of cancers start in the heart, and disease that begins elsewhere seldom spreads to the blood-pumping ...
Sepsis, a life-threatening condition caused by dysregulated host response to infection, remains a major cause of global ...
By choosing Accept All, you consent to the use of all cookies and tracking technologies. By choosing Reject Non-Essential, ...
Therapy Food and Drug Administration (“FDA”) Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despite medication at increased cardiovascular risk ...
Heart disease is becoming increasingly common today. We know that the heart has its own electrical system that regulates its rhythm. When there is a “heart block,” the signal is disrupted — the heart ...
Zebrafish (Danio rerio) were maintained as previously described (19). For morpholino injection experiments followed by tissue-specific analyses, the Tg(myl7:GFP) strain was used (20). All other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results